The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

被引:451
作者
Burslem, George M. [1 ]
Smith, Blake E. [1 ]
Lai, Ashton C. [1 ]
Jaime-Figueroa, Saul [1 ]
McQuaid, Daniel C. [1 ]
Bondeson, Daniel P. [1 ]
Toure, Momar [1 ]
Dong, Hanqing [2 ]
Qian, Yimin [2 ]
Wang, Jing [2 ]
Crew, Andrew P. [2 ]
Hines, John [1 ]
Crews, Craig M. [1 ,3 ,4 ]
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, 219 Prospect St, New Haven, CT 06520 USA
[2] Arvinas LLC, 5 Sci Pk, New Haven, CT USA
[3] Yale Univ, Dept Chem, New Haven, CT 06520 USA
[4] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA
关键词
GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR; BREAST-CANCER; C-MET; TYROSINE KINASES; LUNG-CANCER; HSP90; UBIQUITINATION; RESISTANCE; TIVANTINIB;
D O I
10.1016/j.chembiol.2017.09.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degradation. The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degradation over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degradation leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors. Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degradation using the PROTAC technology and outline the advantages of this degradation-based approach.
引用
收藏
页码:67 / +
页数:14
相关论文
共 64 条
  • [1] Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation
    Abella, JV
    Peschard, P
    Naujokas, MA
    Lin, T
    Saucier, C
    Urbé, S
    Park, M
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (21) : 9632 - 9645
  • [2] Anido J, 2003, CLIN CANCER RES, V9, P1274
  • [3] Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
    Asaoka, Yoshinari
    Tada, Motohisa
    Ikenoue, Tsuneo
    Seto, Motoko
    Imai, Mitsuho
    Miyabayashi, Koji
    Yamamoto, Keisuke
    Yamamoto, Shinzo
    Kudo, Yotaro
    Mohri, Dai
    Isomura, Yoshihiro
    Ijichi, Hideaki
    Tateishi, Keisuke
    Kanai, Fumihiko
    Ogawa, Seishi
    Omata, Masao
    Koike, Kazuhiko
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 394 (04) : 1042 - 1046
  • [4] Met, metastasis, motility and more
    Birchmeier, C
    Birchmeier, W
    Gherardi, E
    Vande Woude, GF
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) : 915 - 925
  • [5] Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
    Bondeson, Daniel P.
    Smith, Blake E.
    Burslem, George M.
    Buhimschi, Alexandru D.
    Hines, John
    Jaime-Figueroa, Saul
    Wang, Jing
    Hamman, Brian D.
    Ishchenko, Alexey
    Crews, Craig M.
    [J]. CELL CHEMICAL BIOLOGY, 2018, 25 (01): : 78 - +
  • [6] Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]
  • [7] HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of Halo Tag Fusion Proteins
    Buckley, Dennis L.
    Raina, Kanak
    Darricarrere, Nicole
    Hines, John
    Gustafson, Jeffrey L.
    Smith, Ian E.
    Miah, Aija H.
    Harling, John D.
    Crews, Craig M.
    [J]. ACS CHEMICAL BIOLOGY, 2015, 10 (08) : 1831 - 1837
  • [8] Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1a
    Buckley, Dennis L.
    Gustafson, Jeffrey L.
    Van Molle, Inge
    Roth, Anke G.
    Tae, Hyun Seop
    Gareiss, Peter C.
    Jorgensen, William L.
    Ciulli, Alessio
    Crews, Craig M.
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2012, 51 (46) : 11463 - 11467
  • [9] Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
    Buckley, Dennis L.
    Van Molle, Inge
    Gareiss, Peter C.
    Tae, Hyun Seop
    Michel, Julien
    Noblin, Devin J.
    Jorgensen, William L.
    Ciulli, Alessio
    Crews, Craig M.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, 134 (10) : 4465 - 4468
  • [10] EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences
    Dassonville, Olivier
    Lozec, Alexandre
    Fischel, Jean Louis
    Milano, Gerard
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 62 (01) : 53 - 61